MedX Announces Non-Brokered Private Placement of Series IV Convertible Loan Notes

Executive Summary

• MedX Health Corp. proposes a non‑brokered private placement to raise up to $5 million through issuance of up to 100 convertible loan notes (Series IV Notes) with a face value of $50,000 each.
• The notes bear 6% annual interest, payable quarterly, mature on 31 Dec 2028, and are convertible at the holder’s option into units at $0.10 per unit (each unit = 1 common share + ½ share purchase warrant).
• Proceeds will be used to redeem existing Series I notes, advance development of the SIAscopy®/DermSecure™ telemedicine platform, expand into occupational‑health markets, and for general corporate purposes.

Key Details

• Offering Size: Up to $5 million (minimum subscription $2.65 million).
• Instrument: Series IV Convertible Loan Notes, up to 100 notes, each with a $50,000 face value.
• Interest Rate: 6% per annum, payable quarterly.
• Maturity: 31 December 2028.
• Conversion Terms: Holder may convert any note at any time before maturity into units at $0.10 per unit.
• Unit Composition: 1 fully paid common share + ½ Share Purchase Warrant.
• Warrant Exercise Price: $0.125 per additional common share; warrants exercisable until the Maturity Date.
• Series I Note Surrender: Holders of existing Series I notes may surrender them to subscribe for Series IV notes.
• Agent Compensation: Qualified agents receive a cash commission equal to 6% of gross proceeds from unit sales they introduce, plus agent warrants equal to 6% of subscriptions they introduce.
• Agent Warrants: Non‑transferable; each entitles the holder to acquire one unit at $0.10 (unit = 1 common share + ½ agent warrant).
• Agent Share Purchase Warrant Exercise Price: $0.125 per additional common share; all agent warrants expire on the Maturity Date if not exercised.
• Use of Proceeds:
• Redemption of any outstanding Series I notes not surrendered via subscription.
• Continued development of the SIAscopy® technology and DermSecure™ telemedicine platform.
• Building out launch of the technology into the occupational‑health marketplace.
• General corporate purposes.

Notable Quotes

• “The capital raised through this private placement will accelerate our growth trajectory, allowing us to further develop our proprietary SIAscopy® imaging technology and expand its application across new market segments,” – John Gevisser, CEO, MedX Health Corp.